Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 764-773

  Venturini, M ^a   Bruzzi, P ^a   Del Mastro, L ^a   Garrone, O ^a   Bertelli, G ^a   Guelfi, M ^a   Pastorino, S ^a   Rosso, R ^a   Sertoli, M R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; RAZOXANE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0029916885     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.764     Document Type: Article

References (29)

1. Johnson TP, Ford L, Warnecke RB, et al: Effect of a National Cancer Institute clinical alert on breast cancer practice patterns. J Clin Oncol 12:1783-1788, 1994
2. Lacey LM, Johnson TP, Warnecke RB: CCOP performance: Accrual, practice patterns and community physician responsiveness. in Kaluzny AD, Warnecke RB, Gillings D (eds): Assessment of the Implementation and Impact of the Community Clinical Oncology Program - Phase II. Chapel Hill, NC, Sheps Center for Health Service Research, University of North Carolina, 1992, pp 1-94
3. Glick JH, Gelber RD, Goldhirsch A, et al: Meeting highlights: Adjuvant therapy for primary breast cancer. J Natl Cancer Inst 84:1479-1485, 1992
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15, 71-85, 1992
5. Valagussa P, Tancini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58:1411-1417, 1986
6. Kardinal CG, Perry MC, Korzun AH, et al: Response to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. Cancer 61:415-419, 1988
7. Houston SJ, Richards MA, Bentley AE, et al: The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer 29A:1513-1518, 1993
8. Bonneterre J, Mercier M: Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. Cancer Treat Rev 19:21-30, 1993 (suppl B)
9. Falkson G, Gelman R, Falkson CI, et al: Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective eastern cooperative oncology group study. J Clin Oncol 9:2153-2161, 1991
10. Mick R, Begg CB, Antman KH, et al: Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies? Breast Cancer Res Treat 13:33-38, 1989
11. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547, 1995
12. Del Mastro L, Garrone O, Sertoli MR, et al: A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. Eur J Cancer 30A:606-610, 1994
13. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
14. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
15. Conte PF, Pronzato P, Rubagotti A, et al: Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Results of a randomized cooperative trial. J Clin Oncol 5:339-347, 1987
16. Conte PF, Gardin G, Pronzato P, et al: In vivo manipulation of human breast cancer growth by estrogens and growth hormone: Kinetic and clinical results. J Steroid Biochem Molec Biol 37:1103-1108, 1990
17. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
18. Michelotti A, Venturini M, Conte PF, et al: Cardioxane (ICRF-187) protects against epirubicin (EPI) induced cardiomiopathy in advanced breast cancer (ABC) patients: A phase III study. Proc Am Soc Clin Oncol 14:98, 1995 (abstr 91)
19. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47:207-214, 1981
20. Cox DR: The regression analysis of binary sequences. J R Stat Soc B 20:215-242, 1958
21. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:187-220, 1972
22. Schneider J, Bak M, Efferth T, et al: P-Glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60:815-818, 1989
23. Chauvin F, Magnet M, Lasset C, et al: Etude des facteurs pronostiques de la réponse à une chimiothérapie de première ligne dans le cancer du sein en phase avancée. Bull Cancer 77:941-947, 1990
24. Pronzato P, Bertelli G, Gardin G, et al: Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. Oncology 50:460-465, 1993
25. Buzdar AU, Legha SS, Hortobagyi GN, et al: Management of breast cancer patients failing adjuvant chemotherapy with Adriamycin-containing regimens. Cancer 47:2798-2802, 1981
26. Gregory WM, Smith P, Richards MA, et al: Chemotherapy of advanced breast cancer: Outcome and prognostic factor. Br J Cancer 68:988-995, 1993
27. Clark GM, Sledge GW Jr, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61, 1987
28. Rouesse J, Friedman S, Guash-Jordan I, et al: Survival effect of systemic therapy on patients developing metastatic breast carcinoma. Breast Cancer Res Treat 15:13-20, 1990
29. Anonymous: Prognostic factors in breast cancer: Biology or chronology? Lancet 340:517-518, 1992